LAMA4 and neoplasm: For example, in hepatocellular carcinoma, LAMA4+ CD90+ endothelial CAFs induce senescence of CD8+ T cells, thereby suppressing anti-tumor immunity; conversely, targeting LAMA4 can reverse immunosuppression and enhance the efficacy of PD-1 blockade (29).